Core Viewpoint - Guangshentang's innovative drug GST-HG131 for hepatitis B treatment has received significant recognition from the American Association for the Study of Liver Diseases (AASLD), with its Phase II clinical trial results accepted for presentation at the 2025 annual meeting, marking a breakthrough in the field [1] Company Summary - Guangshentang's subsidiary, Fujian Guangshenzhonglin Biotechnology Co., Ltd., has achieved a milestone with its drug GST-HG131, which is the first oral HBsAg inhibitor to complete Phase II clinical trials globally [1] - The drug is noted for its good accessibility and patient compliance, indicating potential for widespread use in hepatitis B treatment [1]

智通财经APP讯，广生堂(300436.SZ)发布公告，公司创新药控股子公司福建广生中霖生物科技有限公司 于近日收到全球肝病研究领域的权威专业学术机构 ——美国肝病研究协会(AASLD)(以下简称"美肝会") 的通知，乙肝治疗一类创新药GST-HG131 的临床II 期研究完整结果已被2025年美肝会年会(The Liver Meeting® 2025)正式接受为最新突破摘要口头报告(Late Breaking Abstract Parallel Presentation)，是国际 学术界给予公司乙肝创新药GST-HG131临床研究成果的高度认可。 GST-HG131是目前全球首个完成II期临床的口服HBsAg抑制剂，可及性和患者依从性良好。II期临床试 验显示，在试验患者的HBsAg基线普遍较低的情况下，HBsAg仍下降迅速，最快的患者7天就有约 0.8Log10 IU/mL的降幅，第三组(30mg，BID，三个月给药组)平均降到原值12.88%，降幅87.12%;最高降 到原值2.29%，降幅97.71%;第三组研究中，76.5%的患者达到HBsAg≤100 IU/mL 水平(停药后HBsAg持 续≤10 ...